Company to pursue licensing of its oral probiotic mouthrinse

    Nov. 15, 2006
    Action follows positive clinical results.

    ALACHUA, Florida--Oragenics, Inc. has announced that it will advise a number of consultancy groups to submit plans for the sale or license of this technology. 

    This action will allow Oragenics to focus on its other lead products currently under development, especially its new antibiotic, MU1140, which has the potential to make a significant impact on the global anti-infectives market.

    Based on review and analysis of the positive data from the clinical trial of its groundbreaking oral probiotic mouthrinse, the trial met the company's primary clinical end point by demonstrating a substantial effect of Probiora3 in reducing the levels of specific disease-causing bacteria in the mouths of young, healthy adult subjects. 

    The same trends toward reductions in Streptococcus mutans, a bacterium that attacks teeth, and two bacterial strains associated with gum disease, P. gingivalis and Campylobacter rectus, were observed with both sets of subjects after only one week of product use. 

    C. rectus, for example, was reduced to less than 1 percent of its pretreatment plaque level. This trial also demonstrated that the Probiora3 mouthrinse was safe and well-tolerated during the course of product use.

    Dr. Raman Bedi, the former Chief Dental Officer for England and chairman of Oragenics' Scientific Advisory Committee, stated, "Probiora3 is set to transform the multi-billion dollar worldwide antibacterial mouthwash market. The oral probiotic represents a breakthrough approach to maintaining oral health by utilizing cultures of bacteria commonly found in healthy mouths to provide a natural defense against those bacteria thought to be harmful to teeth and gums."

    Added Dr. Robert Zahradnik, Oragenics' president and CEO, "Our clinically supported probiotic-based approach to maintaining oral health appears to have a promising future. Probiora3's patent-pending blend of beneficial microorganisms can be added to such products as mouthwashes and toothpastes, chewing gum, breath mints/lozenges, and quick-dissolve strips. The early licensing of this technology will allow partner(s) in the oral care and/or food and nutritional supplement industries to take this invention to market by the second half of 2007."